Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Accumulated Expenses (2020 - 2023)

Historic Other Accumulated Expenses for Barinthus Biotherapeutics (BRNS) over the last 4 years, with Q3 2023 value amounting to $1.3 million.

  • Barinthus Biotherapeutics' Other Accumulated Expenses fell 5017.05% to $1.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.3 million, marking a year-over-year decrease of 5017.05%. This contributed to the annual value of $932000.0 for FY2022, which is 2555.91% down from last year.
  • Barinthus Biotherapeutics' Other Accumulated Expenses amounted to $1.3 million in Q3 2023, which was down 5017.05% from $638000.0 recorded in Q2 2023.
  • In the past 5 years, Barinthus Biotherapeutics' Other Accumulated Expenses registered a high of $2.6 million during Q3 2022, and its lowest value of $46000.0 during Q2 2021.
  • For the 4-year period, Barinthus Biotherapeutics' Other Accumulated Expenses averaged around $940545.5, with its median value being $932000.0 (2022).
  • In the last 5 years, Barinthus Biotherapeutics' Other Accumulated Expenses skyrocketed by 209130.43% in 2022 and then plummeted by 5017.05% in 2023.
  • Barinthus Biotherapeutics' Other Accumulated Expenses (Quarter) stood at $266000.0 in 2020, then skyrocketed by 370.68% to $1.3 million in 2021, then dropped by 25.56% to $932000.0 in 2022, then surged by 41.09% to $1.3 million in 2023.
  • Its last three reported values are $1.3 million in Q3 2023, $638000.0 for Q2 2023, and $932000.0 during Q4 2022.